About: drug innovation

Eastern Europe diversity should be considered in EU-wide cancer plan

Having a pan-European cancer control plan is crucial, but some flexibility should be granted to member states in choosing which aspect to prioritise within the framework, said Linda Gibbs from Pfizer Oncology in an interview with EURACTIV.com.
Health 11-07-2019

Czech drug policy shifts toward patients with rare diseases

The Czech government has launched a legislative initiative to improve access to most modern medications and rare disease drugs, Health Minister Adam Vojtěch told EURACTIV in an interview, adding that patients are involved in the decision-making process at a very early stage, including in drafting the law.
Health 28-06-2019

New pharma boss: Next EU Commission should be clear on how to protect innovation

The next EU Commission should take a stronger position on innovation in the pharma sector, the new leader of the European Federation of Pharmaceutical Industries and Associations (EFPIA) told EURACTIV.com in an interview.
Health 21-01-2019

Discussion heats up over stockpiling of generic drugs under patent protection

The Commission has announced its intention to add a manufacturing waiver to supplementary protection certificates (SPC), as part of its upgraded 2015 Single Market Strategy.
Health 30-11-2018

The European Commission should shelve its patent law proposal

The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.
Health 07-11-2018

Greek minister: Effective health and pharma policy needs stronger EU Commission role

A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.
Health 10-10-2018

New drugs: how much are governments paying for innovation?

The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
Health 03-07-2018

EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation

The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.  
Health 08-05-2018

Time to end fragmentation of EU healthcare, experts say

Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
Health 29-01-2018

Health expert: Europe should not put its dominant pharma innovation at risk

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.
Health 10-01-2018

Commission reassures ‘worried’ member states on Health Technology Assessment

The Commission’s upcoming proposal on Health Technology Assessment (HTA) will focus on clinical aspects and leave member states to decide on economic or ethical parts, a European Commission spokesperson told EURACTIV.com.
OpinionPromoted content
Health 12-12-2017

Drugs incentives have saved lives in Europe

Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.

Want to know what's going on in the EU Capitals daily? Subscribe now to our new 9am newsletter.